Acute high-intensity aerobic exercise affects brain-derived neurotrophic factor in mild cognitive impairment: a randomised controlled study

Kate E Devenney, Emer M Guinan, Áine M Kelly, Bibiana C Mota, Cathal Walsh, Marcel Olde Rikkert, Stefan Schneider, Brian Lawlor

ABSTRACT

Objective To investigate the brain-derived neurotrophic factor (BDNF) and cognitive response to a short bout of high-intensity aerobic exercise in older adults with mild cognitive impairment (MCI).

Methods Participants were randomised to one of two testing schedules, completing either a standardised exercise test (group A) or a resting control condition (group B). Blood sampling and cognitive measures (visuospatial learning and memory, sustained attention and executive function) were collected at baseline (T1) and postintervention (T2). An additional measurement of study outcomes was collected after exercise (T3) in group B only.

Results 64 participants (female 53.2%, mean age 70.5±6.3 years) with MCI were recruited. From T1 to T2, serum BDNF (sBDNF) concentration increased in group A (n=35) (median (Md) 4564.61±IQR 5737.23 pg/mL to Md 5173.27±5997.54 pg/mL) and decreased in group B (Md 4593.74±9558.29 pg/mL to Md 3974.66±3668.22 pg/mL) (between-group difference p=0.024, effect size r=0.3). The control group made fewer errors on the sustained attention task compared with the exercise group (p=0.025). Measures of visuospatial learning and memory or executive function did not change significantly between groups.

Conclusion This study is the first to show that a short bout of high-intensity aerobic exercise increases peripheral sBDNF in a population with MCI. However, acute exercise did not improve cognitive performance.

INTRODUCTION

Mild cognitive impairment (MCI) is regarded as a clinical prodrome to Alzheimer’s disease (AD) and other dementias, affecting approximately 15%–20% of people over the age of 65, with 10%–15% of people with MCI progressing to dementia per year. With the ongoing challenges in developing disease-modifying drugs, research into non-pharmacological strategies such as exercise, to prevent dementia or treat cognitive decline has gained increasing importance. A recent update to the American Academy of Neurology practice guideline on MCI now includes a recommendation for regular exercise as part of overall disease management.

A significant body of work has investigated the effects of acute exercise on cognition. Meta-analytical reviews report an overall small positive effect on cognitive performance following acute exercise (mean effect 0.10–0.20), especially in areas of prefrontal cortex-dependent cognition. However, the underlying neurobiological basis of these results has received less attention.

Brain-derived neurotrophic factor (BDNF), a member of the neurotrophin family, plays a predominant role in neuronal plasticity and has been shown to decrease progressively with age, with attenuated loss and a corresponding decrease in cognitive function in MCI cohorts compared with elderly controls. Studies in both animal models and human subjects have described a number of neurobiological changes after an acute bout of exercise and recent evidence...
Figure 1 Study design and schedule of outcome assessments.

postulates BDNF as a mediator of the acute exercise-cognitive relationship in healthy cohorts.14

The transitional phase of MCI along the cognitive continuum presents an opportunity for targeted interventions such as the exercise-induced upregulation of BDNF, which may help slow the rate of cognitive decline. As chronic exercise is the cumulative result of regular bouts of acute exercise, understanding the neurobiological effects of varying acute exercise paradigms is an integral part of building a comprehensive understanding of the long-term effects of exercise on cognitive function.15 This information will help determine the optimal prescription of acute and chronic exercise and add to the emerging research that supports the role of exercise as a natural therapeutic tool to treat cognitive decline in older adults with MCI.

The aim of this study was to examine the effect of a short bout of high-intensity aerobic exercise on serum BDNF (sBDNF) and cognitive performance in individuals with MCI. The working hypothesis was that a short bout of high-intensity exercise would significantly increase sBDNF and cognitive performance compared with a resting control condition.

METHODS

Study Design

Participants were randomised to one of two testing schedules (figure 1) using a computer-generated randomisation list generated by a researcher independent of the study. Treatment allocation was concealed from the investigator. Group A represented the exercise condition while group B was designed to act as the control condition. Outcome measurements were collected at T1 (baseline) and T2 (after the exercise condition in group A and after a resting control condition for group B), with T3 measurements (after exercise) only collected in group B.

Patient and Public Involvement (PPI)

As no funds or time were allocated for PPI, participants were unable to be involved in study design stages. However, participants have been involved in the dissemination.

Participants

Inclusion and exclusion criteria

Participants were screened and recruited from a network of memory clinics (n=38) and through community recruitment (n=26).15 16 Details of the study inclusion and exclusion criteria have been published in the Neuro-Exercise study protocol.16 To summarise, participants had a diagnosis of amnestic MCI due to AD according to the National Institute on Aging and Alzheimer’s Association criteria,17 scored 18–26 on the Montreal Cognitive Assessment (MoCA)18 and were classified as having memory decline but not dementia (Clinical Dementia Rating global score=0.5). Participants met the following inclusion criteria: ECG without significant abnormalities, and medical clearance to undergo a symptom-limited cardiopulmonary exercise test (CPET). Participants were deemed ineligible if they had a diagnosis of AD or other type of dementia; any major psychiatric disorder; unstable cardiac, renal, lung, liver or other severe chronic disease; or engagement in moderate-intensity aerobic exercise training for more than 30 min, three times per week, during the past 2 years.

Study outcomes

Data collection and study interventions were conducted at the Wellcome Trust-Health Research Board Clinical Research Facility in Dublin. Ethical approval was granted from Tallaght Hospital and St James’ Hospital Joint Research and Ethics Committee (REC) and the RECs of referring sites. Due to limited study personnel, the outcome assessor was not blinded to intervention group. All study outcomes were collected in a non-fasting state between the hours of 09:00 and 15:00.

Blood sampling

Participants completed a 10 min resting period prior to baseline blood sampling (T1), with postintervention blood samples collected within a 10 min period following each experimental condition. Serum collection tubes were inverted five times and allowed to coagulate at room temperature before being centrifuged at 1300×g for 10 min at 4°C. The resulting serum was removed, aliquoted and stored at −80°C pending laboratory analysis. Samples and standards were analysed using commercially available BDNF DuoSet ELISA development systems kit (R&D Systems Europe, Oxon, UK) in accordance with the manufacturer’s instruction. Standard curve was constructed and concentration of BDNF in samples was calculated by extrapolation from these curves with results expressed in pg/mL.
**Cognitive performance**

Cognitive tests were administered as per standardised test instructions and included the Cambridge Neuropsychological Test Automated Battery (CANTAB) Paired Associates Learning (PAL) task, a measure of visuospatial learning and memory which was considered the primary cognitive outcome. CANTAB PAL is regarded as a visuospatial memory task, highly sensitive to the memory impairments characteristic in prodromal AD that assesses visual memory and new learning through the testing of conditional learning of pattern–location associations. The Sustained Attention to Response Task (SART), a computerised Go-No-Go paradigm measuring sustained attention, and the Stroop Neuropsychological Screening Test (Stroop) measuring executive function were measured as secondary cognitive outcomes. Testing took approximately 30 min to complete.

**Intervention**

Participants performed a graded CPET to volitional exhaustion as per WHO protocol. The test was performed on a standard COSMED cycle ergometer with oxygen consumption (VO₂) measured using the K4B2 equipment (K4B2 User Manual, COSMED, Italy). ECG and blood pressure measurements were collected at rest and for the duration of the test. The protocol commenced with a 3 min warm-up of unloaded cycling followed by an incremental phase of cycling exercise during which the load increased by 25 W every 2 min until the test was terminated and a 3 min cool down period was performed. The test was terminated when three of the following criteria were met: clinical signs of exhaustion, respiratory quotient ≥1.10, reaching within 10 beats of the predicted heart rate max (220 age) or flattening of the VO₂ uptake curve (≤110 mL increase during the last minute). The control condition in group B consisted of 30 min lying in a semirecumbent position.

**Sample size**

A recent meta-analytical review reported that an acute bout of exercise increased BDNF levels with a moderate effect size (Hedges’ g=0.46, SE=0.08, 95% CI 0.29 to 0.62, z=5.49, p<0.001). Using these values, with 0.05 significance level and 80% power, 32 participants were required per arm to demonstrate an effect size of 0.46 in people with MCI.

**Statistical analysis**

SPSS V.24 (SPSS) was used for analysis with statistical significance set at p<0.05. Kolmogorov-Smirnov test (p>0.05) and visual inspection of histogram and Q-Q plots were used to assess assumptions of normality on all baseline variables. In the case of non-normally distributed data, non-parametric tests were performed.

To standardise baseline data, BDNF data were examined for outliers, with measurements ±2 SDs removed from the mean excluded as per standard approach. Following these criteria, n=9 were removed from further analysis. Second, relative change (%) in BDNF was reported consistent with published reports.

For the primary analysis of study outcomes, between-group differences between T1 and T2 were analysed using an independent samples t-test for normally distributed data and using a Mann-Whitney U test for non-normally distributed data. In the secondary analysis, Friedman’s test and analysis of variance were used to measure the change over time in study outcomes in group B. Wilcoxon signed-rank tests and paired sample t-tests were performed in post hoc analysis to determine the effect size and compare T1–T2, T2–T3 and T1–T3 in group B. As secondary analysis involved multiple comparisons, a Bonferroni correction was applied and alpha level was revised to 0.025. An exploratory analysis of sex differences in BDNF and cognition was performed.

**RESULTS**

Participants were enrolled from 25 February 2016 and data collection for this study ended on 17 July 2017. Sixty-four participants were enrolled and randomised to group A (n=35) or group B (n=29). Missing data included PAL at T1 (participant refusal to complete n=1), SART at T1 (measurement error n=1), missed venepuncture at T2 (n=1) and invalid Stroop T1–T3 (colour blindness n=2, incomplete record sheet n=2). Missing data were treated as missing at random and each missing observation removed from analysis.

**Participant characteristics**

Participant characteristics (age, sex, education, MoCA and body mass index) were similar between groups at baseline (table 1). Participants had a mean age of 70.5 (±6.3) years, 53.2% female, mean MoCA score of 22.0 (±2.5) and the majority (n=38, 59.4%) were highly educated (>13 years). Cardiorespiratory (CR) fitness levels categorised based on age and gender norms revealed a large proportion (n=54, 84.4%) were categorised as very poor

**Table 1 Participant demographics by study group**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Group A: Exercise n=35</th>
<th>Group B: Control n=29</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (M/F)</td>
<td>13/22</td>
<td>17/12</td>
<td>0.14</td>
</tr>
<tr>
<td>Age (years)</td>
<td>71.7 (5.3)</td>
<td>69.0 (7.2)</td>
<td>0.09</td>
</tr>
<tr>
<td>Education (years)</td>
<td>12.5 (3.0)</td>
<td>14.0 (3.2)</td>
<td>0.07</td>
</tr>
<tr>
<td>MoCA</td>
<td>21.6 (2.5)</td>
<td>22.4 (2.6)</td>
<td>0.24</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>27.44 (4.49)</td>
<td>26.14 (4.21)</td>
<td>0.23</td>
</tr>
<tr>
<td>VO₂ max (mL/kg/min)</td>
<td>17.77 (5.15)</td>
<td>21.35 (4.85)</td>
<td>0.002*</td>
</tr>
</tbody>
</table>

Data are presented as mean±SD for normally distributed data and as median ±IQR for non-normally distributed data. Note statistical significance.

P<0.05.

BDI, body mass index; MoCA, Montreal Cognitive Assessment; VO₂, oxygen consumption.
Table 2  Measurement parameters of exercise intensity and duration in the exercise condition for both groups

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group A (n=35)</th>
<th>Group B (n=29)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time (min:s)</td>
<td>09:11 (03:63)</td>
<td>10:25 (02:26)</td>
<td>0.11</td>
</tr>
<tr>
<td>Max watts (W&lt;sub&gt;max&lt;/sub&gt;)</td>
<td>100 (50)</td>
<td>100 (50)</td>
<td>0.34</td>
</tr>
<tr>
<td>Max HR (HR&lt;sub&gt;max&lt;/sub&gt;)</td>
<td>118 (20)</td>
<td>124 (21)</td>
<td>0.27</td>
</tr>
<tr>
<td>Peak lactate (mmol/L)</td>
<td>5.0 (4.8)</td>
<td>4.4 (2.7)</td>
<td>0.16</td>
</tr>
<tr>
<td>Lactate change (mmol/L)</td>
<td>2.9 (3.5)</td>
<td>2.8 (3.5)</td>
<td>0.33</td>
</tr>
<tr>
<td>Respiratory exchange ratio (RER)</td>
<td>1.06 (0.12)</td>
<td>1.06 (0.07)</td>
<td>0.95</td>
</tr>
</tbody>
</table>

Primary analysis

Between-group difference in BDNF and cognitive performance

BDNF concentration increased in group A (exercise condition) from T1 (Md=4593.74±9558.29 pg/mL<sup>1</sup>) to T2 (Md=5173.27±5997.54 pg/mL<sup>1</sup>) and decreased in group B (resting control condition) from T1 (Md=4593.74±9558.29 pg/mL<sup>1</sup>) to T2 (Md=3974.66±3668.22 pg/mL<sup>1</sup>) (p=0.01, r=0.38), and increased significantly from T2 (Md=3974.66±3668.22 pg/mL<sup>1</sup>) to T3 following completion of a short bout of high-intensity aerobic exercise (Md=4790.90±6713.17 pg/mL<sup>1</sup>) (p=0.001, r=0.48). The relative change in BDNF is consistent with the findings of the primary analysis, with the mean % relative change in BDNF concentration from T2 to T3 (postexercise) in group B of 15.7% (±22.1%).

Stroop CWS (Wilks' lambda=0.668, F<sub>(2,26)=6.461</sub>, p=0.005, multipartial η<sup>2</sup>=0.33) and SART RT (F<sub>(2,29)=0.036</sub>, p=0.005) changed significantly over time within group B. There were significant increases in Stroop CWS following participation in the exercise condition from T1 (M=75.25±26.97) to T3 (M=83.93±21.47) (mean increase=−8.67, 95% CI −13.55 to −3.80) (p=0.001, ES 0.34), indicating improved performance. SART RT reduced significantly in response to the control condition from T1 (Md=154.57 ms±79.80 ms) to T2 (Md=123.61 ms±79.80 ms) (p=0.004, ES 0.37), with no significant change in SART commission errors. Additionally, PALTEA did not change significantly over time (F<sub>(2,29)=7.000</sub>, p=0.03) although a non-significant decrease in error rate was observed from T1 (Md=44±22) to T2 (Md=33±29) (z=−2.130, p=0.03, ES 0.27) and from T1 to T3 (Md=28±30) (z=−2.232, p=0.026, ES 0.29).

Secondary analysis

Change over time within group B

Repeated measures analysis within group B indicated a statistically significant difference in sBDNF across the three time points (p=0.005). sBDNF reduced significantly during the resting condition between T1 (Md=4593.74±9558.29 pg/mL<sup>1</sup>) and T2 (Md=3974.66±3668.22 pg/mL<sup>1</sup>) (p=0.01, r=0.38), and increased significantly from T2 (Md=3974.66±3668.22 pg/mL<sup>1</sup>) to T3 following completion of a short bout of high-intensity aerobic exercise (Md=4790.90±6713.17 pg/mL<sup>1</sup>) (p=0.001, r=0.48). The relative change in sBDNF is consistent with the findings of the primary analysis, with the mean % relative change in sBDNF concentration from T2 to T3 (postexercise) in group B of 15.7% (±22.1%).

Stroop CWS (Wilks' lambda=0.668, F<sub>(2,26)=6.461</sub>, p=0.005, multipartial η<sup>2</sup>=0.33) and SART RT (F<sub>(2,29)=0.036</sub>, p=0.005) changed significantly over time within group B. There were significant increases in Stroop CWS following participation in the exercise condition from T1 (M=75.25±26.97) to T3 (M=83.93±21.47) (mean increase=−8.67, 95% CI −13.55 to −3.80) (p=0.001, ES 0.34), indicating improved performance. SART RT reduced significantly in response to the control condition from T1 (Md=154.57 ms±79.80 ms) to T2 (Md=123.61 ms±79.80 ms) (p=0.004, ES 0.37), with no significant change in SART commission errors. Additionally, PALTEA did not change significantly over time (F<sub>(2,29)=7.000</sub>, p=0.03) although a non-significant decrease in error rate was observed from T1 (Md=44±22) to T2 (Md=33±29) (z=−2.130, p=0.03, ES 0.27) and from T1 to T3 (Md=28±30) (z=−2.232, p=0.026, ES 0.29).

Results are presented in table 4.

Sex differences in acute exercise BDNF and cognitive response

There was a significant difference in SART RT pre-to-post exercise in female participants (Pre Md=154.57 ms±79.80 ms) compared with male participants (Pre Md=130.08 ms±76.45 ms) (p=0.025, ES 0.28). There were no significant differences between male and female sedentary people in response to a high-intensity exercise or resting control condition.
Table 3  Effect of exercise on BDNF and cognitive outcomes

<table>
<thead>
<tr>
<th>Variables</th>
<th>Baseline (T1)</th>
<th>Follow-up (T2)</th>
<th>Change within group</th>
<th>P value</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>BDNF (pg/mL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exercise</td>
<td>4642.51 (7065.08)</td>
<td>5308.17 (6355.73)</td>
<td>123.96 (2690.97)</td>
<td>0.07</td>
<td>n/a</td>
</tr>
<tr>
<td>Control</td>
<td>5330.86 (10 346.65)</td>
<td>4477.95 (5002.88)</td>
<td>−530.79 (1427.44)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BDNF (pg/mL) outliers excluded</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exercise</td>
<td>4564.61 (5737.23)</td>
<td>5173.27 (5997.54)</td>
<td>135.86 (1709.74)</td>
<td>0.024*</td>
<td>0.3</td>
</tr>
<tr>
<td>Control</td>
<td>4593.74 (9558.29)</td>
<td>3974.66 (3668.22)</td>
<td>−530.79 (838.43)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CANTAB PALTEA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exercise</td>
<td>44 (30)</td>
<td>46 (23)</td>
<td>.26 (10.29)</td>
<td>0.08</td>
<td>n/a</td>
</tr>
<tr>
<td>Control</td>
<td>44 (22)</td>
<td>33 (29)</td>
<td>−6 (15.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stroop CWS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exercise</td>
<td>66.42 (28.51)</td>
<td>70.48 (30.66)</td>
<td>4.00 (16.00)</td>
<td>0.456</td>
<td>n/a</td>
</tr>
<tr>
<td>Control</td>
<td>75.25 (26.97)</td>
<td>77.93 (27.42)</td>
<td>1.00 (13.00)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SART commission errors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exercise</td>
<td>2.5 (5)</td>
<td>4 (4)</td>
<td>0.5 (5)</td>
<td>0.025*</td>
<td>0.28</td>
</tr>
<tr>
<td>Control</td>
<td>3 (4)</td>
<td>2 (3)</td>
<td>−1 (3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SART reaction time (ms)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exercise</td>
<td>142.04 (83.50)</td>
<td>128.07 (74.42)</td>
<td>4.84 (39.24)</td>
<td>0.055</td>
<td>n/a</td>
</tr>
<tr>
<td>Control</td>
<td>154.57 (78.90)</td>
<td>123.61 (79.62)</td>
<td>27.66 (51.36)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Primary analysis: Between-group differences T1 and T2 time points. Data are presented for the exercise (group A) and control group (group B) as mean±SD for normally distributed data and as median±IQR for non-normally distributed data. P value represents within-group differences with statistical significance.

*P<0.05.

BDNF, brain-derived neurotrophic factor; CWS, colour word score; PALTEA, Paired Associates Learning Total Errors Adjusted; SART, Sustained Attention to Response Task; n/a, not applicable.

participants in exercise BDNF response and other cognitive measures.

DISCUSSION

This study examined the changes in sBDNF concentration and cognitive performance in response to a short bout of high-intensity aerobic exercise in individuals with MCI. To the best of our knowledge, this is the first study to show that a short bout of high-intensity aerobic exercise increases peripheral sBDNF in a population with MCI. The results support previous work in this area which has primarily focused on young healthy cohorts. However, in the current study secondary analysis demonstrated only modest within-group post exercise cognitive change.

The findings of the present study are consistent with previous studies that have reported increases in peripheral BDNF in response to acute exercise protocols in healthy adult cohorts and in clinical populations. To date, few studies have examined the effect of acute aerobic exercise on peripheral BDNF in older adults or MCI. However, a recent study by Tsai et al found an acute bout of 30 min of moderate-intensity aerobic exercise significantly increased sBDNF levels

Table 4  Secondary analysis measuring change over time in study outcomes within group B

<table>
<thead>
<tr>
<th>Variables</th>
<th>Baseline T1</th>
<th>Postcontrol condition T2</th>
<th>Postexercise condition T3</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>BDNF (pg/mL) outliers excluded</td>
<td>4593.74 (9558.29)</td>
<td>3974.66 (3668.22)</td>
<td>28 (30)</td>
<td>0.005*</td>
</tr>
<tr>
<td>CANTAB PALTEA</td>
<td>44 (22)</td>
<td>33 (29)</td>
<td>83.93 (21.47)</td>
<td>0.005*</td>
</tr>
<tr>
<td>Stroop CWS</td>
<td>75.25 (26.97)</td>
<td>77.93 (27.42)</td>
<td>28 (30)</td>
<td>0.03</td>
</tr>
<tr>
<td>SART commission errors</td>
<td>3 (4)</td>
<td>2 (3)</td>
<td>83.93 (21.47)</td>
<td>0.005*</td>
</tr>
<tr>
<td>SART reaction time (ms)</td>
<td>154.57 (78.90)</td>
<td>123.61 (79.62)</td>
<td>28 (30)</td>
<td>0.03</td>
</tr>
</tbody>
</table>

P value represents within group change over time with statistical significance.

Bonferroni correction applied and alpha level *P<0.025.

BDNF, brain-derived neurotrophic factor; CWS, colour word score; PALTEA, Paired Associates Learning Total Errors Adjusted; SART, Sustained Attention to Response Task.
in a group (n=25) of older adults with amnestic MCI. In agreement, our findings indicate that older adults with MCI, despite being in the early stages of the neurodegenerative process, retain the ability to increase peripheral BDNF concentration following acute aerobic exercise of varying intensity and duration.

Across the literature, the % BDNF change in response to exercise varies widely in healthy and clinical populations, with an average increase of 60% reported in peripheral BDNF levels following acute exercise. The magnitude of BDNF change in response to exercise is dependent on blood lactate concentration, duration and intensity of exercise and is transient in nature. The within-group sBDNF change in response to exercise observed in our results was 7.07% (group A) and 15.7% (group B). Studies of similar study design that examined comparable graded exercise protocols in healthy young cohorts and clinical populations reported higher % BDNF change in response to exercise (15%–30% relative change from baseline). Coelho et al examined the exercise BDNF response in 21 older adults with AD and 18 healthy older adults and found significant increases in BDNF plasma levels in both groups (p=0.001; f=13.63; df=37) with a relative change of 22% and 16%, respectively. Despite comparable performance of the exercise condition (duration and intensity) in both groups, group B demonstrated a higher % increase in sBDNF after exercise. In contrast to existing literature, the BDNF upregulation did not appear to be driven by lactate but may be explained by the significantly higher CR fitness observed in group B.

CR fitness in the present study cohort was low, with n=59 (92.2%) of participants categorised as very poor (<20th percentile) or poor (20th–40th percentiles). While evidence supports strong associations between higher levels of CR fitness and cognitive function, the relationship between BDNF and CR fitness is unclear, with some studies reporting a positive association between the two immediately after exercise and others reporting an inverse relationship. A meta-analytical review by Dinoff et al reported significant associations between VO2 peak and effect sizes in studies measuring the effects of acute exercise on BDNF, indicating greater increases in peripheral BDNF after acute exercise in those with greater CR fitness. In the present study, we could not compare BDNF response in high and low-fit participants due to the homogeneity in the study sample but no correlation was found between CR fitness (VO2 max) and baseline sBDNF levels.

Despite the consistently reported positive effects of acute exercise on cognitive performance, the findings of the current study do not support the beneficial effect of acute exercise on cognitive performance in MCI. In contrast, the resting control condition demonstrated a decrease in sBDNF and improved performance on the SART, a task that activates the cortical and subcortical attentional networks. While it is possible that the resting control condition may have reduced circulating cortisol levels similar to quiet meditation practice, the mechanisms underpinning the observed effect cannot be fully explained with further research required.

Recent meta-analytical reviews report that the BDNF and cognitive response to exercise may vary in a sex-dependent manner. Subgroup analysis by Dinoff et al revealed significant increase in BDNF after acute exercise in males but not in females. In contrast, our findings did not reveal sex differences in BDNF response to acute exercise. However, we did observe sex differences in SART RT with females gaining significant improvement in RT following acute exercise compared with males. RTs are known to slow and become more variable with age, with significant sex differences reported in RT variability. Despite recent reports of sex differences in the cognitive response in executive function tasks to exercise, we did not observe any sex differences in other cognitive measures in response to acute exercise.

The results of the present study should be viewed in the context of a number of potential limitations. First, peripheral measurement of BDNF is not without limitations, as processes occurring centrally in the brain may not have a measurable influence on peripheral blood markers; nor may circulating BDNF have any influence on brain function within the time frame of this experiment. Second, secondary analysis of change in cognitive performance (group B) demonstrated improvement in executive function after exercise. However, group B completed an additional measurement of cognitive measures (T3), thereby increasing the risk of type I error due to practice effects of repeated tests which may be an important confounder of these results. Finally, other factors that may mediate BDNF response to exercise were not examined. The BDNF val66met polymorphism, a genetic variant that occurs in 33% of the population, and the apolipoprotein E gene ε4 allele, the most prevalent genetic risk factor for late-onset AD, affect the expression of BDNF and alter susceptibility to neuropathology and may be an important consideration in understanding responders to exercise.

CONCLUSIONS
The results of this study indicate that a single session of high-intensity exercise is feasible in an MCI cohort, enhances circulating sBDNF concentration but does not improve visuospatial learning and memory, sustained attention or executive function. This research adds to the literature which postulates that the impaired BDNF profile in MCI cohorts may be amenable to exercise training as a strategy to address the declining BDNF profile.

Acknowledgements We acknowledge the assistance and support of the Wellcome Trust–HRB Clinical Research Facility at St James’ Hospital in providing a dedicated environment for the conduct of high-quality clinical research activities.

Collaborators Members of the NeuroExercise Study Group (in alphabetical order by name): Dr. Justine A. Aaronson, Department of Medical Psychology, Radboud University Medical Center, Nijmegen, The Netherlands; Dr. Vera Abeln, Institute of Movement and Neurosciences, German Sport University Cologne, Germany; Dr.
Jurgen A.H.R Claassen, Department of Geriatric Medicine, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands; Dr. Robert F. Coen, Mercer’s Institute for Research on Ageing, St. James’s Hospital, Dublin, Ireland; Dr. Damien Ferguson, Department of Neurology, St. James’s Hospital, Dublin, Ireland; Prof. Roy P.C. Kessels, Department of Medical Psychology, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands; Prof. Romain Meusens, Human Physiology Research Group, Vrije Universiteit Brussels, Belgium; Prof. Christian Montag, Institute of Psychology and Education, Ulm University, Germany and Key Laboratory for Neuroinformation/Center for Information in Medicine and School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, China; Dr Ross T. Murphy, St. James’s Hospital, Dublin, Ireland; Prof. M. Cristina Polidori, Ageing Clinical Research, University Hospital of Cologne, Germany; Prof. Martin Reuter, University of Bonn, Department of Psychology and Center for Economics & Neuroscience, Laboratory of Neurogenetics, Bonn, Germany; Marit Sanders, Department of Geriatric Medicine, Radboud Alzheimer Centre, Radboud University Medical Center, Nijmegen, The Netherlands; Prof. Heiko K. Strüder, Institute of Movement and Neurosciences, German Sport University Cologne, Germany; Tim Stuckenschneider, Institute of Movement and Neurosciences, German Sport University Cologne, Germany; Prof. Bernd Weber, Department of Epileptology, University Hospital Bonn, Germany.

Contributors KED, EMG, BL, MOR and SS were involved in study conception and design. AK and BCM completed the laboratory analysis and assisted with BDNF analysis. CW advised and assisted on statistical analysis. KED and EMG drafted the manuscript with input from all authors on each version of the paper. All authors have approved the final version of this paper prior to submission.

Funding This study is part of the NeuroExercise project which has been supported by The EU Joint Programme–Neurodegenerative Disease Research (JPND), Local funding was provided through the Health Research Board, Ireland.

Disclaimer The sponsors had no involvement in the study design, collection, analysis and interpretation of data or in writing of the report or decision to submit the paper for publication.

Competing interests None declared.

Patient consent for publication Obtained.

Ethics approval Research and Ethics Committees (REC): Tallaght Hospital/ St James’ Hospital Joint REC, Mater Misericordiae University Hospital REC, St Patrick’s University Hospital REC and St Vincent’s University Hospital REC.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Data are available upon reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES


